表紙:アルツハイマー病治療薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
市場調査レポート
商品コード
1029301

アルツハイマー病治療薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)

Alzheimer's Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 140 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=116.46円
アルツハイマー病治療薬の世界市場:業界動向、市場シェア・規模・成長率・機会および予測(2021年~2026年)
出版日: 2021年09月16日
発行: IMARC Services Private Limited
ページ情報: 英文 140 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアルツハイマー病治療薬の市場規模は、2020年に63億4,000万米ドルに達し、2021年から2026年の間に6.50%のCAGRで拡大すると予想されています。

アルツハイマー型認知症は、脳のいくつかの領域における神経細胞の変性を特徴とする疾患です。記憶、言語、思考、行動などの認知機能の低下を引き起こします。アルツハイマー型認知症の一般的な症状としては、うつ病、記憶障害、抑制力の低下、思考や推論の問題などがあります。アルツハイマー病の診断には、身体検査、血液検査、脳画像検査、精神状態や神経心理学的検査などが行われます。その結果に基づいて、医師は症状を緩和するためにさまざまな薬を処方します。アルツハイマー病治療薬は、脳内の神経細胞間のメッセージ伝達に関わる化学物質である神経伝達物質の機能に影響を与えます。

アルツハイマー病治療薬の市場動向

  • 糖尿病、肥満、心臓病、高血圧、座りっぱなしの生活、不健康な食生活、喫煙などは、アルツハイマー型認知症を発症させる可能性を高める要因とされています。これらの疾患や生活習慣の増加、高齢者人口の増加は、市場成長の主な要因となっています。さらに、大手製薬企業は、この病気を予防し、認知機能を長期的に改善する薬剤の開発に注力しています。また、遠隔医療サービスの拡大とオンライン薬局の普及が、市場成長を支えています。これらのプラットフォームにより、遠隔地での疾病診断や薬剤提供が可能になりました。また、現在、アデュカヌマブ、Solanezumab、インスリンなど、さまざまなアルツハイマー病治療薬が後期臨床試験段階にあります。これらの薬剤の開発は、今後数年間、市場成長を促進すると予想されます。

当レポートは、世界のアルツハイマー病治療薬市場について調査しており、業界動向、市場予測、薬物クラス・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。また、 COVID-19の不確実性を念頭に置いて、さまざまな最終用途産業に対するパンデミックの直接的および間接的な影響を継続的に追跡および評価しています 。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のアルツハイマー病治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 薬物クラス別の市場セグメンテーション

  • ドネペジル
  • ガランタミン
  • リバスチグミン
  • メマンチン
  • その他

第7章 流通チャネル別の市場セグメンテーション

  • 病院薬局
  • 小売薬局
  • オンラインストア
  • その他

第8章 地域別の市場セグメンテーション

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 国別の市場セグメンテーション

第9章 SWOT分析

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業 のプロファイル
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
図表

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2020
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2020
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2020
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players
目次
Product Code: SR1020F251_Report

The global alzheimer's drugs market reached a value of US$ 6.34 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.50% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Alzheimer's is a disease characterized by the degeneration of nerve cells in several areas of the brain. It causes loss of cognitive function, such as memory, language, thinking and behavior. The common symptoms of Alzheimer's include depression, memory impairment, loss of inhibitions, and problems with thinking and reasoning. It is usually diagnosed by performing physical exams, blood tests, brain imaging, and mental status and neuropsychological testing. According to the results, doctors prescribe different medications to alleviate symptoms. Alzheimer's drugs influence the functions of neurotransmitters, the chemicals involved in carrying messages between nerve cells in the brain.

Alzheimer's Drugs Market Trends:

  • Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions. The market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's drugs are presently under late-stage clinical trials, including Aducanumab, Solanezumab and Insulin. The development of these drugs is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global alzheimer's drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc and Teva Pharmaceutical Industries Limited. Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis